Burr Financial Services LLC Sells 262 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Burr Financial Services LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,632 shares of the medical research company’s stock after selling 262 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.7% of Burr Financial Services LLC’s portfolio, making the stock its 17th biggest holding. Burr Financial Services LLC’s holdings in Thermo Fisher Scientific were worth $1,010,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hudson Valley Investment Advisors Inc. ADV lifted its stake in Thermo Fisher Scientific by 2.9% in the third quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,063 shares of the medical research company’s stock worth $12,411,000 after purchasing an additional 556 shares during the last quarter. JFS Wealth Advisors LLC raised its stake in Thermo Fisher Scientific by 43.1% in the third quarter. JFS Wealth Advisors LLC now owns 269 shares of the medical research company’s stock worth $166,000 after buying an additional 81 shares in the last quarter. Diversify Wealth Management LLC raised its stake in Thermo Fisher Scientific by 11.9% in the third quarter. Diversify Wealth Management LLC now owns 3,549 shares of the medical research company’s stock worth $2,046,000 after buying an additional 378 shares in the last quarter. ADE LLC purchased a new stake in Thermo Fisher Scientific in the third quarter worth about $210,000. Finally, Pinnacle Associates Ltd. grew its holdings in Thermo Fisher Scientific by 1.5% in the third quarter. Pinnacle Associates Ltd. now owns 34,712 shares of the medical research company’s stock worth $21,472,000 after purchasing an additional 511 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $550.43 on Thursday. The stock has a 50 day moving average of $601.50 and a 200-day moving average of $583.56. The company has a market capitalization of $210.26 billion, a P/E ratio of 34.51, a P/E/G ratio of 3.66 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $433.15 and a 12 month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the company posted $5.69 EPS. The business’s revenue was up .2% on a year-over-year basis. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,300 shares of company stock valued at $6,831,268 over the last ninety days. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Sanford C. Bernstein cut their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a report on Thursday, October 24th. Bank of America raised their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Redburn Atlantic began coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Stephens began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.